Cibc World Market Inc. Purchases 21,885 Shares of Delcath Systems, Inc. (NASDAQ:DCTH)

by · The Markets Daily

https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&h=150&zc=2&src=https://www.marketbeat.com/logos/delcath-systems-inc-logo.png
Cibc World Market Inc. boosted its position in Delcath Systems, Inc. (NASDAQ:DCTH – Free Report) by 21.3% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 124,717 shares of the company’s stock after acquiring an additional 21,885 shares during the period. Cibc World Market Inc. owned 1.17% of Delcath Systems worth $727,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Tower Research Capital LLC TRC boosted its holdings in Delcath Systems by 107.8% in the 1st quarter. Tower Research Capital LLC TRC now owns 4,663 shares of the company’s stock valued at $26,000 after purchasing an additional 2,419 shares during the period. Geode Capital Management LLC boosted its holdings in Delcath Systems by 4.8% in the 1st quarter. Geode Capital Management LLC now owns 62,733 shares of the company’s stock valued at $361,000 after purchasing an additional 2,851 shares during the period. BlackRock Inc. boosted its holdings in Delcath Systems by 22.3% in the 1st quarter. BlackRock Inc. now owns 16,632 shares of the company’s stock valued at $96,000 after purchasing an additional 3,032 shares during the period. Millennium Management LLC bought a new position in Delcath Systems in the 2nd quarter valued at $40,000. Finally, Virtu Financial LLC bought a new position in Delcath Systems in the 2nd quarter valued at $64,000. 85.15% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Delcath Systems news, Director Rosalind Advisors, Inc. bought 100,000 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were bought at an average price of $2.40 per share, for a total transaction of $240,000.00. Following the transaction, the director now directly owns 1,038,828 shares in the company, valued at $2,493,187.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Delcath Systems news, Director Rosalind Advisors, Inc. bought 100,000 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were bought at an average price of $2.40 per share, for a total transaction of $240,000.00. Following the transaction, the director now directly owns 1,038,828 shares in the company, valued at $2,493,187.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO John Purpura bought 14,505 shares of the firm’s stock in a transaction that occurred on Friday, October 13th. The stock was acquired at an average price of $3.44 per share, for a total transaction of $49,897.20. Following the transaction, the chief operating officer now owns 41,526 shares in the company, valued at $142,849.44. The disclosure for this purchase can be found here. Insiders have acquired a total of 204,505 shares of company stock worth $511,597 in the last 90 days. 21.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. HC Wainwright raised their price target on shares of Delcath Systems from $17.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, August 15th. StockNews.com raised shares of Delcath Systems to a “sell” rating in a report on Tuesday, November 21st. Canaccord Genuity Group lifted their price objective on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, September 7th. Roth Mkm lifted their price objective on shares of Delcath Systems from $10.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, August 16th. Finally, BTIG Research lifted their price objective on shares of Delcath Systems from $19.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, August 15th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Read Our Latest Stock Analysis on DCTH

Delcath Systems Stock Performance

NASDAQ DCTH opened at $2.74 on Wednesday. Delcath Systems, Inc. has a 52-week low of $2.25 and a 52-week high of $7.99. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.11 and a current ratio of 3.30. The company has a market capitalization of $60.41 million, a P/E ratio of -0.82 and a beta of 0.48. The company has a fifty day moving average of $3.24 and a 200-day moving average of $4.63.

Delcath Systems (NASDAQ:DCTH – Get Free Report) last issued its earnings results on Monday, November 13th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10). The business had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $0.68 million. Delcath Systems had a negative return on equity of 2,571.64% and a negative net margin of 2,079.17%. As a group, equities research analysts predict that Delcath Systems, Inc. will post -2.43 EPS for the current fiscal year.

Delcath Systems Company Profile

(Free Report)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Further Reading